Loading...

Cytokinetics, Incorporated

CYTK•NASDAQ
Healthcare
Biotechnology
$65.32
$-0.16(-0.24%)
U.S. Market opens in 47h 43m

Cytokinetics, Incorporated (CYTK) Stock Overview

Explore Cytokinetics, Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap8B
P/E Ratio-10.15
EPS (TTM)$-6.54
ROE1.73%
Fundamental Analysis

AI Price Forecasts

1 Month$55.70
3 Months$61.79
1 Year Target$67.86

CYTK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cytokinetics, Incorporated (CYTK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.35, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $67.86.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -10.15 and a market capitalization of 8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.24%
5-Day Change
-1.55%
1-Month Change
8.83%
3-Month Change
3.01%
6-Month Change
12.95%
Year-to-Date (YTD) Change
2.80%
1-Year Change
61.96%
3-Year Change
70.46%
5-Year Change
142.02%
All-Time (Max) Change
-32.38%

Contact Information

https://www.cytokinetics.com
650 624 3000
350 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

498 Employees
IPO DateApr 30, 2004
CountryUS
Actively Trading

Frequently Asked Questions